FORM 4	
--------	--

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>*</sup>	2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer				
		(Check all applicable)				
PETERS WILLIAM J	Amphastar Pharmaceuticals, Inc. [					
	AMPH ]	Director 10% Owner				
(Last) (First) (Middle)	3. Date of Earliest Transaction (MM/DD/YYYY)	X_Officer (give title below) Other (specify below)				
(Lust) (First) (Minute)		CFO, EVP & Treasurer				
C/O AMPHASTAR	2/8/2022					
PHARMACEUTICALS, INC., 11570						
6TH STREET						
(Street)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line)				
RANCHO CUCAMONGA, CA 91730 (City) (State) (Zip)		X _ Form filed by One Reporting Person Form filed by More than One Reporting Person				

# Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

				· ·		·	e e		
1. Title of Security (Instr. 3)	2. Trans. Date	(Instr. 8) or Disposed of (D)		. ,	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form:	7. Nature of Indirect Beneficial		
		Code	v	Amount	(A) or (D)	Price		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Common Stock	2/8/2022	M		10000	( )	\$14.95	116042	D	
Common Stock	2/8/2022	S <mark>(1)</mark>		10000	D	\$26.95	106042	D	

# Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

							ť	01	, ,	, ,			,		
1. Title of Derivate Security (Instr. 3)	Conversion or Exercise Price of Derivative	3. Trans. Date	3A. Deemed Execution Date, if any	Code		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)6. Date Exercisable Expiration Date		Expiration Date Securities Underlying Derivative Security			Derivative Security (Instr. 5)	y Securities 5) Beneficially	Ownership Form of Derivative	Beneficial Ownership (Instr. 4)	
	Security			Code	V	(A)	(D)	Date Exercisable	Expiration Date		Amount or Number of Shares			Direct (D) or Indirect (I) (Instr. 4)	
Employee Stock Option (right to buy)	\$14.95	2/8/2022		М			10000	<u>(2)</u>	3/26/2025	Common Stock	10000	\$0	48074	D	

# **Explanation of Responses:**

- (1) The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2021.
- (2) Shares subject to the option are fully vested and immediately exercisable.

# **Reporting Owners**

C/O AMPHASTAR PHARMACEUTICALS, IN 11570 6TH STREET	Relationships							
	Director	10% Owner	Officer	Other				
PETERS WILLIAM J C/O AMPHASTAR PHARMACEUTICALS, INC. 11570 6TH STREET RANCHO CUCAMONGA, CA 91730			CFO, EVP & Treasurer					

Signatures

/s/	William	J.	Peters	

Signature of Reporting Person

Date

2/9/2022

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.